MET and non-small cell lung carcinoma: In the subsequent INSIGHT study, 67% of EGFR TKI-resistant NSCLC patients with MET gene amplification had an objective therapeutic response to treatment with the MET inhibitor tepotinib combined with gefitinib (183).